Linea 1: 2011

Linea 1: 2011
IF
Grezzo
IF
Norm.
Morabito F, Gentile M, Mazzone C, Rossi D, Di Raimondo F, Bringhen S, Ria R, Offidani M,
Patriarca F, Nozzoli C, Petrucci MT, Benevolo G, Vincelli I, Guglielmelli T, Grasso M, Marasca
R, Baldini L, Montefusco V, Musto P, Cascavilla N, Majolino I, Musolino C, Cavo M, Boccadoro
M, Palumbo A. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalanprednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood.
2011 Nov 24;118(22):5759-66. PubMed PMID: 21951682.
10,558
4,000
Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, Patriarca F, Nozzoli C, Cavo
M, Offidani M, Floridia M, Berretta S, Vallone R, Musto P, Lauria F; for the GIMEMA (Gruppo
Italiano Malattie Ematologiche dell'Adulto) Myeloma Working Party. Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective
survey of 50 patients. Cancer. 2011 Aug 25. PubMed PMID: 21932386.
5,131
3,000
IF
Grezzo
IF
Norm.
La Starza R, Crescenzi B, Nofrini V, Barba G, Matteucci C, Brandimarte L, Pierini V, Testoni N,
Musto P, Paolini S, Gianfelici V, Storlazzi CT, Pierini A, Berchicci L, Gorello P, Mecucci C. FISH
analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. Leuk
Res. 2011 Sep 13. PubMed PMID: 21920603.
2,555
2,000
Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P. Azacitidine for
the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an
italian compassionate program. Cancer. 2011 Jul 14. PubMed PMID: 21761399.
5,418
6,000
Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, Pogliani E, Angelucci
E, Fioritoni G, Musto P, Greco M, Criscuolo M, Fianchi L, Vignetti M, Santini V, Hohaus S,
Mecucci C, Leone G. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia. 2011 Jul 15. PubMed PMID:
21760590.
8,296
4,000
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P,
Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell
transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin
Oncol. 2011 Aug 1;29(22):3016-22. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.
PubMed PMID: 21730266.
18,970
7,500
Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, Baldini L, Tosi P,
Bringhen S, Offidani M, Omedè P, Neri A, D'Auria F, Bochicchio GB, Cavo M, Boccadoro M,
Palumbo A. Primary plasma cell leukemia in the era of new drugs: Has something changed?
Crit Rev Oncol Hematol. 2011 Jun 28. PubMed PMID: 21719304.
5,269
6,000
Petruzziello F, Zeppa P, Ciancia G, Cozzolino I, Fernandez LS, Cervasio M, Musto P, D'Auria
F, Vita G, Morabito F, Piro E, Ponti MR, Pettinato G, Ciancia R, Pane F, Catalano L. Cytological and histological detection of amyloid deposits in bone marrow of patients affected by
multiple myeloma. Leuk Lymphoma. 2011 Dec;52(12):2304-7. PubMed PMID: 21718137.
2,492
2,000
Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F,
Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, Crisà E, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/
intolerant to imatinib. Leuk Res. 2011 Sep;35(9):1164-9. PubMed PMID: 21705080.
2,555
2,000
10,555
4,000
Fayers PM, Palumbo A, Hulin C, Waage A, Wijermans P, Beksaç M, Bringhen S, Mary JY,
Gimsing P, Termorshuizen F, Haznedar R, Caravita T, Moreau P, Turesson I, Musto P, Benboubker L, Schaafsma M, Sonneveld P, Facon T; Nordic Myeloma Study Group; Italian
Multiple Myeloma Network; Turkish Myeloma Study Group; Hemato-Oncologie voor
Volwassenen Nederland; Intergroupe Francophone du Myélome; European Myeloma
Network. Thalidomide for previously untreated elderly patients with multiple myeloma:
meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011
Aug 4;118(5):1239-47. PubMed PMID: 21670471.
IF
Grezzo
IF
Norm.
Sacchi S, Marcheselli R, Lazzaro A, Morabito F, Fragasso A, Di Renzo N, Balleari E, Neri S,
Quarta G, Ferrara R, Vigliotti ML, Polimeno G, Musto P, Consoli U, Zoboli A, Buda G, Pastorini A, Masini L. A randomized trial with melphalan and prednisone versus melphalan and
prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for
autologous stem cell transplant. Leuk Lymphoma. 2011 Oct;52(10):1942-8. PubMed PMID:
21663513.
2,397
2,000
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B,
Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C,
Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach
T, Pasqualucci L, Rabadan R, Falini B. BRAF mutations in hairy-cell leukemia. N Engl J Med.
2011 Jun 16;364(24):2305-15. PubMed PMID: 21663470.
47,050
7,500
Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, Cascavilla N, Montefusco V, Lupo B, Liberati AM, Crippa C, Rossini F, Passera R, Patriarca F, Cafro AM, Omedè P,
Carella AM, Peccatori J, Catalano L, Caravita T, Musto P, Petrucci MT, Boccadoro M, Palumbo
A. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia. 2011 Oct;25(10):1627-31. PubMed PMID: 21637283.
8,296
4,000
Bardi A, Cavazzini F, Rigolin GM, Tammiso E, Volta E, Pezzolo E, Formigaro L, Sofritti O,
Daghia G, Ambrosio C, Rizzotto L, Abass AE, D'Auria F, Musto P, Cuneo A. Employment of
oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal
zone lymphoma. J Biomed Biotechnol. 2011;2011:691493. PubMed PMID: 21629757
1,225
2,000
Ria R, Musto P, Reale A, Guariglia R, Iodice G, Dammacco F, Vacca A. 90Y-ibritumomab
tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive
non-Hodgkin lymphoma. J Nucl Med. 2011 Jun; 52(6):891-5. PubMed PMID: 21571787.
6,424
8,000
Offidani M, Corvatta L, Morabito F, Gentile M, Musto P, Leoni P, Palumbo A. How to treat
patients with relapsed/refractory multiple myeloma: evidence-based information and
opinions. Expert Opin Investig Drugs. 2011 Jun;20(6):779-93. Review. PubMed PMID:
21470070.
4,220
3,000
Musto P, D'Auria F. The clinical and biological role of CD20 membrane antigen modulation
under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders. Expert Opin Biol Ther. 2011 May;11(5):551-7. Review. PubMed
PMID: 21385115.
3,215
6,000
Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco
A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin
A, Rota-Scalabrini D, Visani G, Rigacci L. Bendamustine with or without rituximab in the
treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J
Haematol. 2011 May;153(3):351-7. PubMed PMID: 21371003.
4,597
3,000
IF
Grezzo
IF
Norm.
Ferrara F, Musto P. Hypomethylating agents for the treatment of acute myeloid leukemia in
the elderly: for all, none, or which patients? Cancer. 2011 Sep 1;117(17):3879-81. PubMed
PMID: 21287537.
5,418
6,000
Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia
G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute
Leukemia Working Party: coordinator Sergio Amadori). Primary plasma cell leukemia: a
retrospective multicenter study of 73 patients. Ann Oncol. 2011 Jul;22(7):1628-35. PubMed
PMID: 21252060.
5,647
3,000
Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A,
Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P,
Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. Complete response
correlates with long-term progression-free and overall survival in elderly myeloma treated
with novel agents: analysis of 1175 patients. Blood. 2011 Mar 17;117(11):3025-31. PubMed
PMID: 21228328.
10,555
4,000
Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C,
Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation. Cancer. 2011 Dec 16. PubMed
PMID: 22179904.
5,131
3,000
Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR,
Cascavilla N, Falchi L, Zallio F, Callea V, Maura F, Martinelli S, Piciocchi A, Reda G, Foà R; on
behalf of the GIMEMA Chronic Lymphoproliferative Disorders Working Party. An Italian
retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients. Br J Haematol. 2011 Dec 9. PubMed PMID:
22150204.
4,942
3,000
D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani
O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A,
Ferrara F, Palumbo A, Pagano L, Musto P. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a
retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2011 Oct
29. PubMed PMID: 22039089.
6,452
6,000
D'Arena G, Deaglio S, Laurenti L, De Martino L, De Feo V, Fusco BM, Carella AM, Cascavilla
N, Musto P. Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem. 2011
Jun;11(6):480-5. PubMed PMID: 21561409.
2,622
4,000
Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, Bongarzoni V, D'Arco
A, Di Renzo N, Fazzi R, Franco G, Marasca R, Mulè A, Musso M, Musto P, Pennese E, Piccin
A, Rota-Scalabrini D, Visani G, Rigacci L. Bendamustine with or without rituximab in the
treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J
Haematol. 2011 May;153(3):351-7. PubMed PMID: 21371003.
4,597
3,000
IF
Grezzo
IF
Norm.
Ferrara F, Musto P. Hypomethylating agents for the treatment of acute myeloid leukemia in
the elderly: for all, none, or which patients? Cancer. 2011 Sep 1;117(17):3879-81. PubMed
PMID: 21287537.
5,418
6,000
Pagano L, Valentini CG, De Stefano V, Venditti A, Visani G, Petrucci MT, Candoni A, Specchia
G, Visco C, Pogliani EM, Ferrara F, Galieni P, Gozzetti A, Fianchi L, De Muro M, Leone G, Musto P, Pulsoni A; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute
Leukemia Working Party: coordinator Sergio Amadori). Primary plasma cell leukemia: a
retrospective multicenter study of 73 patients. Ann Oncol. 2011 Jul;22(7):1628-35. PubMed
PMID: 21252060.
5,647
3,000
Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, Genuardi M, Romano A,
Liberati AM, Siniscalchi A, Petrucci MT, Nozzoli C, Patriarca F, Offidani M, Ria R, Omedè P,
Bruno B, Passera R, Musto P, Boccadoro M, Sonneveld P, Palumbo A. Complete response
correlates with long-term progression-free and overall survival in elderly myeloma treated
with novel agents: analysis of 1175 patients. Blood. 2011 Mar 17;117(11):3025-31. PubMed
PMID: 21228328.
10,555
4,000
Ferrario A, Pulsoni A, Olivero B, Rossi G, Vitolo U, Tedeschi A, Merli F, Rigacci L, Stelitano C,
Goldaniga M, Mannina D, Musto P, Rossi F, Gamba E, Baldini L. Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: Phase 2 study of the Italian Lymphoma Foundation. Cancer. 2011 Dec 16. PubMed
PMID: 22179904.
5,131
3,000
Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla
N, Falchi L, Zallio F, Callea V, Maura F, Martinelli S, Piciocchi A, Reda G, Foà R; on behalf of the
GIMEMA Chronic Lymphoproliferative Disorders Working Party. An Italian retrospective
study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic
lymphocytic leukaemia patients. Br J Haematol. 2011 Dec 9. PubMed PMID: 22150204.
4,942
3,000
D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, Villani
O, Onofrillo D, Falcone A, Specchia G, Semenzato G, Di Renzo N, Mastrullo L, Venditti A,
Ferrara F, Palumbo A, Pagano L, Musto P. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a
retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol. 2011 Oct
29. PubMed PMID: 22039089.
6,452
6,000
D'Arena G, Deaglio S, Laurenti L, De Martino L, De Feo V, Fusco BM, Carella AM, Cascavilla
N, Musto P. Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem. 2011
Jun;11(6):480-5. PubMed PMID: 21561409.
2,622
4,000
D'Arena G, Gobbi PG, Broglia C, Sacchi S, Quarta G, Baldini L, Iannitto E, Falcone A, Guariglia R, Pietrantuono G, Villani O, Martorelli MC, Mansueto G, Sanpaolo G, Cascavilla N,
Musto P; Gimema (Gruppo Italiano Malattie Ematologiche Dell'Adulto); Multiple Myeloma
Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group. Pamidronate
versus observation in asymptomatic myeloma: final results with long-term follow-up of a
randomized study. Leuk Lymphoma. 2011 May;52(5):771-5. PubMed PMID: 21299465.
2,492
4,000
IF
Grezzo
IF
Norm.
Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena
G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, Tedeschi A, Ambrosetti A, Gaidano G, Leone G, Foà R. The coexistence of chronic lymphocytic leukemia
and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J
Hematol. 2011 Dec;86(12):1007-12. PubMed PMID: 21953617.
3,576
3,000
D’Arena G, Rossi G, Minervini MM, Savino L, D’Auria F, Laurenti L, Del Principe MI, Deaglio
S, Biagi A, De Martino L, De Feo V, Statuto T, Musto P, Del Poeta G. Circulating regulatory
T cells in “clinical” monoclonal B-cell lymphocytosis Int J Immunopathol Pharmacol. 2011
Oct;24(4):915-923. PubMed PMID: 22230398
2,685
2,000
Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore
D, Specchia G, De Paolis MR, Mazza P, Pietrantuono G, Petrini M. Lenograstim reduces the
incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res. 2011 Jul;35(7):899-903. PubMed PMID:
21134693.
2,555
2,000
Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi
N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri
V, De Placido S, Cartenì G. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 2011 Jan;107(2):234-9. PubMed PMID:
20590545.
2,865
3,000
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A,
Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC,
Bochicchio AM, Chiaulon G, Gallo M, Boni L. Primary tumor response to preoperative
chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic
results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011 Jul 10;29(20):2773-80.
PubMed PMID: 21606427.
17,793
7,500
Stacchiotti S, Palassini E, Sanfilippo R, Vincenzi B, Arena MG, Bochicchio AM, De Rosa P,
Nuzzo A, Turano S, Morosi C, Dei Tos AP, Pilotti S, Casali PG. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. Ann
Oncol. 2011 Apr 4. PubMed PMID: 21464156.
5,643
3,000
Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati
G, Aprile G, Giaquinta S, Torri V, Bardelli A, Gion M, Martoni A. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in
high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol. 2011
Nov;22(11):2424-30. PubMed PMID: 21385884.
5,647
3,000
Tartarone A, Lerose R, Gallucci G, Ardito R, Aieta M. Evaluation of molecular prognostic
and predictive factors: an important step towards personalized treatment in non small cell
lung cancer. Med Oncol. 2011 Jun 2. PubMed PMID: 21633836.
1,227
2,000
IF
Grezzo
Tartarone A. Exemestane for breast-cancer prevention. N Engl J Med. 2011
Sep15;365(11):1056; author reply 1057-8. PubMed PMID: 21916646.
IF
Norm.
53,486
0
Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A,Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, GonzálezTrujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI; ATHENA Study Group. First-line
bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast
cancer: safety and efficacy in an open-label study in 2,251 patients. Ann Oncol. 2011
Mar;22(3):595-602. PubMed PMID: 20819780.
5,647
1,200
Lerose R, Musto P, Aieta M, Papa C, Tartarone A. Off-label use of anti-cancer drugs between
clinical practice and research: the Italian experience. Eur J Clin Pharmacol. 2011 Dec 14.
PubMed PMID:22166932
3,032
4,000
Kett DH, Azoulay E, Echeverria PM, Vincent JL; Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units:
analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med.
2011 Apr;39(4):665-70. PubMed PMID: 21169817.
6,265
1,200
Ruffini E, Van Raemdonck D, Detterbeck F, Rocco G, Thomas P, Venuta F; European Society of Thoracic Surgeons Thymic Questionnaire Working Group. Management of thymic
tumors: a survey of current practice among members of the European Society of Thoracic
Surgeons. J Thorac Oncol. 2011 Mar;6(3):614-23. PubMed PMID: 21266921.
4,040
1,200
Bianchino G, Cittadini A, Grieco V, Traficante A, Zupa A, Improta G, Aieta M, Sgambato A.
Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 genes and cancer risk in a Southern
Italian population: a case-control study. Anticancer Res. 2011 Apr;31(4):1359-65. PubMed
PMID: 21508386.
1,428
2,000
Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin
EF 3rd, Wulfkuhle JD. Protein pathway activation mapping of brain metastasis from lung and
breast cancers reveals organ type specific drug target activation. J Proteome Res. 2011 Jul
1;10(7):3089-97. PubMed PMID: 21574647.
5,132
3,000
Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, De Tullio G, Ferrucci A, De Luisi
A, Moschetta M, Mangialardi G, Catacchio I, Basile A, Guarini A, Zito A, Ditonno P, Musto
P, Dammacco F, Ribatti D, Vacca A. Four proteins governing overangiogenic endothelial cell
phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene.
2011 Oct 3. PubMed PMID: 21963844.
7,414
8,000
IF
Grezzo
IF
Norm.
De Luisi A, Ferrucci A, Coluccia AM, Ria R, Moschetta M, De Luca E, Pieroni L, Maffia M, Urbani A, Di Pietro G, Guarini A, Ranieri G, Ditonno P, Berardi S, Caivano A, Basile A, Cascavilla N, Capalbo S, Quarta G, Dammacco F, Ribatti D, Vacca A. Lenalidomide restrains motility
and overangiogenic potential of bone marrow endothelial cells in patients with active
multiple myeloma. Clin Cancer Res. 2011 Apr 1;17(7):1935-46. PubMed PMID: 21307145.
7,338
4,000
Amoroso MR, Matassa DS, Laudiero G, Egorova AV, Polishchuk RS, Maddalena F, Piscazzi
A, Paladino S, Sarnataro D, Garbi C, Landriscina M, Esposito F. TRAP1 and the proteasome
regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular
ubiquitination of specific mitochondrial proteins. Cell Death Differ. 2011 Oct 7. PubMed
PMID: 21979464.
9,050
4,000
Pozzi V, Mazzotta M, Lo Muzio L, Sartini D, Santarelli A, Renzi E, Rocchetti R, Tomasetti M,
Ciavarella D, Emanuelli M. Inhibiting proliferation in KB cancer cells by RNA interferencemediated knockdown of nicotinamide N-methyltransferase expression. Int J Immunopathol
Pharmacol. 2011 Jan-Mar;24(1):69-77. PubMed PMID: 21496389.
3,061
4,000
Iacobucci I, Ferrari A, Lonetti A, Papayannidis C, Paoloni F, Trino S, Storlazzi CT, Ottaviani E,
Cattina F, Impera L, Abbenante MC, ,Vitale A, Potenza L, Paolini S, Soverini S, Pane F, Luppi
M, Foà R, Baccarani M, Martinelli G. Department of Hematology and Oncological Sciences
"L. and A. Seràgnoli" S.Orsola Malpighi Hospital, University of Bologna, Italy.CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.
Clin Cancer Res. 2011 Dec 1;17(23):7413-23.
6,743
4,000
Bisceglia M, Galliani C, Giannatempo G, Lauriola W, Bianco M, D'angelo V, Pizzolitto S, Vita
G, Pasquinelli G, Magro G, Dor DB. Solitary fibrous tumor of the central nervous system:
a 15-year literature survey of 220 cases (August 1996-July 2011). Adv Anat Pathol. 2011
Sep;18(5):356-92. PubMed PMID: 21841406.
3,087
3,000
Galliani CA, Bisceglia M, Lastilla G, Parafioriti A, Vita G, Rosai J. TTF-1 in embryonal tumors:
an immunohistochemical study of 117 cases. Am J Surg Pathol. 2011 Sep;35(9):1422-5.
PubMed PMID: 21836486.
4,106
3,000
Bruno M, D'antona GI, Vita G, Perrone G, Fiordelisi F, Bisceglia M. Subcutaneous Ewing
sarcoma/PNET as a second cancer in a previously irradiated young patient. an uncommon
type of post-irradiation soft tissue sarcoma. Pathologica. 2011 Apr;103(2):43-5. Review.
PubMed PMID: 21797142.
0
0,100
0,912
2,000
Vita G, Borgia L, Di Giovannantonio L, Bisceglia M. Dedifferentiated endometrioid adenocarcinoma of the uterus: a clinico pathologic study of a case. Int J Surg Pathol. 2011
Oct;19(5):649-52. PubMed PMID: 21531695.
IF
Grezzo
Bisceglia M, Perri F, Tucci A, Tardio M, Panniello G, Vita G, Pasquinelli G. Primary malignant
melanoma of the esophagus: a clinic pathologic study of a case with comprehensive literature review. Adv Anat Pathol. 2011 May;18(3):235-52. Review. PubMed PMID: 21490441.
IF
Norm.
3,221
3,000
Pichiorri F, De Luca L, Aqeilan RI. MicroRNAs: new players in multiple myeloma, Frontiers in
Genetics 2011. PMID 22303318
0
0,100
De Ceglie A, Filiberti R, Blanchi S, Fontana V, Fisher DA, Grossi E, Lacchin T, De Matthaeis M,
Ignomirelli O, Cappiello R, Casa DD, Foti M, Laterza F, Rosati R, Annese V, Iaquinto G, Conio
M. History of cancer in first degree relatives of Barrett's esophagus patients: a case-control
study.Clin Res Hepatol Gastroenterol. 2011 Dec;35(12):831-8.
0
0,100
Totale 358,435
182,4
Linea 2: 2011
IF
Grezzo
IF
Norm.
Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad
K, Hansen L,Tjønneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R,
Schütze M, Steffen A, Bamia C,Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R,Tumino R,
Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram
IT, Rodríguez L,Travier N, Sánchez MJ, Huerta JM, Ardanaz E, Larrañaga N, Jirström K, Manjer J,
Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E. Oral contraceptive use and
reproductive factors and risk of ovarian cancer in the European Prospective Investigation into
Cancer and Nutrition. Br J Cancer. 2011 Oct 25;105(9):1436-42. PubMed PMID: 21915124.
4,831
3,000
Gram IT, Lukanova A, Brill I, Braaten T, Lund E, Lundin E, Overvad K,Tjønneland A, Clavel-Chapelon F, Chabbert-Buffet N, Bamia C,Trichopoulou A, Zylis D, Masala G, Berrino F, Galasso R,
Tumino R, Sacerdote C, Gavrilyuk O, Kristiansen S, Rodríguez L, Bonet C, Huerta JM, Barricarte
A, Sánchez MJ, Dorronsoro M, Jirström K, Almquist M, Idahl A, Bueno-de-Mesquita HB, Braem M,
Onland-Moret C,Tsilidis KK, Allen NE, Fedirko V, Riboli E, Kaaks R. Cigarettesmoking and risk of
histological subtypes of epithelial ovarian cancer in the EPIC cohort study. Int J Cancer. 2011 Jun
15. PubMed PMID: 21678398.
4,722
3,000
Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC,
Overvad K, Hansen L, Tjønneland A, Rinaldi S, Romieu I, Boutron-Ruault MC, Clavel-Chapelon
F, Lukanova A, Boeing H, Schütze M, Benetou V, Palli D, Berrino F, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram
IT, Rodríguez L, Duell EJ, Sánchez MJ, Huerta JM, Ardanaz E, Amiano P, Khaw KT, Wareham N,
Riboli E. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control. 2011 Aug;22(8):1075-84.
PubMed PMID: 21637986.
3,199
3,000
Totale
12,752
9
Linea 3: 2011
IF
Grezzo
IF
Norm.
Mainenti PP, Iodice D, Segreto S, Storto G, Magliulo M, De Palma GD, Salvatore M, Pace L. Colorectal cancer and 18FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol. 2011 Mar 21;17(11):1427-33. PubMed PMID: 21472100.
2,292
2,000
Barbieri V, Sanpaolo P, Genovesi D. Interval between breast-conserving surgery and start of
radiation therapy in early-stage breast cancer is not predictive of local recurrence: a single-institution experience. Clin Breast Cancer. 2011 Apr;11(2):114-20. PubMed PMID: 21569997.
2,790
4,000
Barbieri V, Sanpaolo P, Genovesi D. Prognostic impact of triple negative phenotype in conservatively treated breast cancer. Breast J. 2011 Jul-Aug;17(4):377-82. PMID: 21615820.
1,425
2,000
Sanpaolo P, Barbieri V, Genovesi D. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early
stage breast cancer: a retrospective clinical study.Eur J Surg Oncol. 2011 Oct;37(10):876-82.
PubMed PMID: 21824742.
0
6,000
Sanpaolo P, Barbieri V, Genovesi D, Fusco V, Ausili Cèfaro G. Biologically effective dose and
breast cancer conservative treatment: is duration of radiation therapy really important? Breast
Cancer Res Treat. 2011 Dec 28.PubMed PMID: 22203436.
4,696
6,000
Sanpaolo P, Barbieri V, Pedicini P, Fusco V. Her-2 prognostic value in very early-stage breast
cancer: a single-institution retrospective analysis. Med Oncol. 2011 Feb 26. PubMed PMID:
21359639.
1,227
2,000
Chiumento C, Montagna A, Clemente S, Cozzolino M, Fusco V. A retrospective analysis after
low-dose-rate prostate brachytherapy with permanent (125)I seed implant: clinical and dosimetric results in 70 patients. Tumori. 2011 May-Jun;97(3):335-40. PubMed PMID: 21789012.
1,014
1,000
Chiumento C, Fiorentino A, Castaldo G, Fusco V. A case of thyroid metastasis of nasopharyngeal
cancer.Tumori. 2011 Sep-Oct;97(5):24e-6e. PMID:22158505
1,014
1,000
Totale 14,458
24
Tot. Pubblicazioni n.64 Tot. IF Normalizzato 215,4